Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA9 | Q16790 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6349793 | 0.76 | LMNA (0.43) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL296106 | 0.74 | LMNA (0.48) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL28631127 | 0.72 | LMNA (0.34) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL4398512 | 0.71 | CA12 (0.56) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL8612973 | 0.70 | LMNA (0.40) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL15570602 | 0.69 | CA1 (0.42) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL8907824 | 0.68 | LMNA (0.38) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL4319784 | 0.67 | LMNA (0.61) | LMNATHRBCYP2C19KMT2ACA12 | |
| [18F]Fluoromisonidazole SCHEMBL18401354 | 0.67 | KMT2A (0.67) | LMNATHRBCYP2C19KMT2ACA12 | |
| [18F]Fluoromisonidazole SCHEMBL13020421 | 0.67 | KMT2A (0.67) | LMNATHRBCYP2C19KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855828-B1 | Detection of hypoxia | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050026974-A1 | Detection of hypoxia | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2005-02-03 | — | — | US | disclosed |
| US-6252087-B1 | COMPLEXING WITH A PROTEIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026974-A1 | Detection of hypoxia | HIF1A, HIF1AN, HYOU1 | LMNA 4407/4885THRB 3873/4885CYP2C19 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.